Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real-world study.
effectiveness
immunotherapy
melanoma
pharmacoepidemiology
retrospective study
targeted therapy
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
07
04
2021
received:
28
10
2020
accepted:
09
04
2021
pubmed:
12
4
2021
medline:
24
12
2021
entrez:
11
4
2021
Statut:
ppublish
Résumé
We aimed to examine the survival outcomes plus patient and treatment characteristics of advanced melanoma patients treated with first-line immunotherapy (IT), targeted therapy (TT), and chemotherapy (CTH) and compare findings with information from pivotal trials for each therapy. We retrospectively reviewed the use of systematic IT, TT and CTH therapies in melanoma patients in four Queensland public hospitals. We estimated median duration of overall survival (OS) and survival rates (6 months, 1, and 2 years) using Kaplan-Meier methods. We compared our findings to those of clinical trials. Five hundred three patients who met the inclusion criteria were divided into three groups based on the first-line treatment: IT 232; TT 157; and CTH 114. OS was 18 months with IT (95% CI 13, 22); 12 months with TT (95% CI 8, 15); and 5 months with CTH (95% CI 5, 6). The demographic characteristics, treatment protocols, and durations for IT and TT were generally consistent with trials but fewer patients in our study had subsequent therapy than in the trials. The OS in our study was slightly lower than the OS reported in trials. The OS of novel cancer therapy in the real world was lower than seen in trials but is expected given these are patients who have a poorer prognosis. A future study could investigate the impact of prognostic factors on survival in the longer term. This study provides evidence that we can use routinely collected real-world data to evaluate the effectiveness of checkpoint and kinase inhibitors in patients with advanced melanoma.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1371-1379Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Investigat Dermatol. 2016;136(6):1161-1171.
Mahler V, Diepgen T. The epidemiology of skin cancer. Br J Dermatol. 2002;146(61):1-6.
Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Investigat Dermatol. 2009;129(7):1666-1674.
de Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. Europ J Cancer. 2004;40(16):2355-2366.
Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer. Pharmacoeconomics. 2011;29(10):863-874.
Guy GP Jr, Ekwueme DU, Tangka FK, Richardson LC. Melanoma treatment costs: a systematic review of the literature, 1990-2011. Am J Prevent Med. 2012;43(5):537-545.
Melanoma Patient Australia. The facts about Melanoma; 2019. https://melanomapatients.org.au/about-melanoma/melanoma-facts/. Accessed July 25, 2019.
Australia Institute of Heatlh and Welfare. Cancer data in Australia; 2019. https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/data. Accessed September 20, 2019.
Malissen N, Grob J-J. Metastatic melanoma: recent therapeutic progress and future perspectives. Drugs. 2018;78:1179-1209.
Cancer Research Institue. Immunotherapy for Melanoma; 2019. https://www.cancerresearch.org/immunotherapy/cancer-types/melanoma. Accessed July 25, 2019.
Baitsch L, Baumgaertner P, Devêvre E, et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Investigat. 2011;121(6):2350-2360.
Ascierto PA, Kirkwood JM, Grob J-J, et al. The role of BRAF V600 mutation in melanoma. J Translat Med. 2012;10:85.
Skovlund E, Leufkens H, Smyth J. The use of real-world data in cancer drug development. Europ J Cancer. 2018;101:69-76.
Gaudy-Marqueste C, Dussouil AS, Carron R, et al. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Europ J Cancer. 2017;84:44-54.
Ibrahim T, Mateus C, Baz M, Robert C. Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study. Cancer Immunol Immunother. 2018;67(10):1571-1578.
Lang B, Peveling-Oberhag A, Faidt D, et al. Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting. Med Oncol. 2018;35(3):24.
Mangana J, Cheng PF, Kaufmann C, et al. Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Res. 2017;27(4):358-368.
Polkowska M, Ekk-Cierniakowski P, Czepielewska E, Kozłowska-Wojciechowska M. Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data. Europ J Clin Pharmacol. 2018;75(3):329-334.
Polkowska M, Ekk-Cierniakowski P, Czepielewska E, Wysoczanski W, Matusewicz W, Kozlowska-Wojciechowska M. Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data. J Cancer Res Clin Oncol. 2017;143(10):2087-2094.
Tietze JK, Forschner A, Loquai C, et al. The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: a retrospective multicenter study. Oncotarget. 2018;9(76):34336.
Valpione S, Carlino MS, Mangana J, et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: a multi-institutional retrospective study. Europ J Cancer. 2018;91:116-124.
Ugurel S, Loquai C, Kahler K, et al. A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. Ann Oncol. 2015;26(3):573-582.
Atkinson V, Sandhu S, Hospers G, et al. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib named patient program (DESCRIBE II). Melanoma Res. 2020;30(3):261-267.
Martin-Algarra S, Hinshelwood R, Mesnage S, et al. Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a named patient program. Melanoma Res. 2019;29(5):527-532.
Cancer Alliance Queensland. The Queensland Cancer Register; 2018. https://cancerallianceqld.health.qld.gov.au/qc. Accessed July 20, 2018.
American Medical Association. ICD-10 Code for Multiple myeloma C90.0; 2018. https://coder.aapc.com/icd-10-codes/C90.0. Accessed June 25, 2018.
Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853-1862.
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. New Engl J Med. 2015;372(26):2521-2532.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl J Med. 2015;373(1):23-34.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New Engl J Med. 2017;377(14):1345-1356.
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med. 2011;364(26):2507-2516.
Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28(10):2581-2587.
Long G, Flaherty K, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631-1639.
Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451.
Australian Ministry of Health. Public Summary Documents; 2021. https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/public-summary-documents-by-product. Accessed February 15, 2021.
Forschner A, Eichner F, Amaral T, Keim U, Garbe C, Eigentler TK. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German central malignant melanoma registry (CMMR). J Cancer Res Clin Oncol. 2017;143(3):533-540.
Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. New Engl J Med. 2015;372(1):30-39.
National Cancer Institute. Melanoma Treatment; 2021. https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq#link/_841. Accessed April 6, 2021.
Stokes WA, Lentsch EJ. Age is an independent poor prognostic factor in cutaneous head and neck melanoma. Laryngoscope. 2014;124(2):462-465.
Balch CM, Soong S-J, Gershenwald JE, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20(12):3961-3968.
Sileni VC, Pigozzo J, Ascierto PA, et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res. 2014;33(1):1-7.
Dagogo-Jack I, Lanfranchi M, Gainor JF, et al. A retrospective analysis of the efficacy of Pembrolizumab in melanoma patients with brain metastasis. J Immunother. 2017;40(3):108-113.